Literature DB >> 15193385

Japanese encephalitis subunit vaccine composed of virus-like envelope antigen particles purified from serum-free medium of a high-producer J12#26 cell clone.

Eiji Mutoh1, Toyokazu Ishikawa, Akihisa Takamizawa, Takeshi Kurata, Tetsutaro Sata, Asato Kojima.   

Abstract

A stable cell clone, J12#26, which continuously secretes large amounts of the envelope (E) antigen of Japanese encephalitis (JE) virus (J. Virol. 77 (2003) 8745) was adapted to serum-free medium. The J12#26 antigen possessed hemagglutinating activity, as well as the viral E and M proteins. More than 10 and 1mg of the antigen quantified with the licensed JE vaccine (JE-VAX) as a standard by E-ELISA and protein determination, respectively, were recovered from 500 ml of serum-free medium by membrane ultrafiltration, Sephacryl S-300 chromatography, sucrose gradient centrifugation and Sephadex G-25 chromatography. SDS-PAGE and Western blot analyses confirmed the high yield and purity of the J12#26 E antigen, which was comprised of small spherical virus-like particles (VLP) of approximately 25 nm in diameter. This antigen induced in mice without adjuvant neutralizing antibody (NT Ab) titers, as high as or higher than the licensed JE vaccine, and complete protection against challenge with wild-type virus. These results suggest that the J12#26 antigen is a promising second-generation JE subunit vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193385     DOI: 10.1016/j.vaccine.2003.12.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Histidine at residue 99 and the transmembrane region of the precursor membrane prM protein are important for the prM-E heterodimeric complex formation of Japanese encephalitis virus.

Authors:  Ying-Ju Lin; Suh-Chin Wu
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine.

Authors:  Michelle H Nelson; Evandro Winkelmann; Yinghong Ma; Jingya Xia; Peter W Mason; Nigel Bourne; Gregg N Milligan
Journal:  Vaccine       Date:  2010-11-04       Impact factor: 3.641

3.  Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus.

Authors:  Shigefumi Okamoto; Hironori Yoshii; Masaaki Matsuura; Asato Kojima; Toyokazu Ishikawa; Takami Akagi; Mitsuru Akashi; Michiaki Takahashi; Koichi Yamanishi; Yasuko Mori
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

4.  Oleic acid Enhances Dengue Virus But Not Dengue Virus-Like Particle Production from Mammalian Cells.

Authors:  Suwipa Ramphan; Sathiporn Suksathan; Nitwara Wikan; Puey Ounjai; Kanpong Boonthaworn; Poramate Rimthong; Tapanee Kanjanapruthipong; Suchin Worawichawong; Anan Jongkaewwattana; Nuttaporn Wongsiriroj; Duncan R Smith
Journal:  Mol Biotechnol       Date:  2017-10       Impact factor: 2.695

5.  Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens.

Authors:  Miwa Kuwahara; Eiji Konishi
Journal:  Clin Vaccine Immunol       Date:  2010-07-28

6.  Genotype I of Japanese Encephalitis Virus Virus-like Particles Elicit Sterilizing Immunity against Genotype I and III Viral Challenge in Swine.

Authors:  Yi-Chin Fan; Jo-Mei Chen; Jen-Wei Lin; Yi-Ying Chen; Guan-Hong Wu; Kuan-Hsuan Su; Ming-Tang Chiou; Shang-Rung Wu; Ji-Hang Yin; Jiunn-Wang Liao; Gwong-Jen J Chang; Shyan-Song Chiou
Journal:  Sci Rep       Date:  2018-05-10       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.